These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Susceptibility of aerobic gram-negative bacilli to aminoglycosides. Effects of 45 months of amikacin as first-line aminoglycoside therapy. Saavedra S, Vera D, Ramírez-Ronda CH. Am J Med; 1986 Jun 30; 80(6B):65-70. PubMed ID: 3014877 [Abstract] [Full Text] [Related]
3. Surveillance of aminoglycoside resistance. European data. Van Landuyt HW, Boelaert J, Glibert B, Gordts B, Verbruggen AM. Am J Med; 1986 Jun 30; 80(6B):76-81. PubMed ID: 3089007 [Abstract] [Full Text] [Related]
5. Control of emergence of multi-resistant gram-negative bacilli by exclusive use of amikacin. Ruiz-Palacios GM, Ponce de Leon S, Sifuentes J, Ponce de Leon S, Calva JJ, Huazano F, Ontiveros C, Ojeda F, Bobadilla M. Am J Med; 1986 Jun 30; 80(6B):71-5. PubMed ID: 3089006 [Abstract] [Full Text] [Related]
8. Tobramycin, amikacin, sissomicin, and gentamicin resistant Gram-negative rods. Drasar FA, Farrell W, Maskell J, Williams JD. Br Med J; 1976 Nov 27; 2(6047):1284-7. PubMed ID: 1000196 [Abstract] [Full Text] [Related]
9. In vitro susceptibility of gentamicin and/or tobramycin resistant gram-negative bacilli to seven aminoglycosides. Watanakunakorn C, Kauffman CA. Infection; 1978 Nov 27; 6(3):111-5. PubMed ID: 98451 [Abstract] [Full Text] [Related]
10. Clinical and microbiologic consequences of amikacin use during a 42-month period. Berk SL, Alvarez S, Ortega G, Verghese A, Holtsclaw-Berk SA. Arch Intern Med; 1986 Mar 27; 146(3):538-41. PubMed ID: 3954526 [Abstract] [Full Text] [Related]
11. In vitro aminoglycoside resistance of gram-negative bacilli and staphylococci isolated from blood in Sweden 1980-1984. Bengtsson S, Bernander S, Brorson JE, Dornbusch K, Forsgren A, Hallander H, Henning C, Holm S, Malmborg AS, Nilsson L. Scand J Infect Dis; 1986 Mar 27; 18(3):257-63. PubMed ID: 3738436 [Abstract] [Full Text] [Related]
12. Treatment of pediatric infections with amikacin as first-line aminoglycoside. Shulman ST, Yogev R. Am J Med; 1985 Jul 15; 79(1A):43-50. PubMed ID: 4025367 [Abstract] [Full Text] [Related]
14. Resistance to aminoglycoside antibiotics of gram-negative bacilli isolated in Canadian hospitals. Duncan IB, Cheung EY, Haldane EV, Jackson FL, McNaughton RD, Morisset RA, Noble MA, Rennie RP, Ronald AR, Smith JA. Can Med Assoc J; 1981 May 01; 124(9):1165-7. PubMed ID: 7237336 [Abstract] [Full Text] [Related]
15. Antibiotic resistance patterns during aminoglycoside restriction. Young EJ, Sewell CM, Koza MA, Clarridge JE. Am J Med Sci; 1985 Dec 01; 290(6):223-7. PubMed ID: 3936358 [Abstract] [Full Text] [Related]
16. [Comparison of bactericidal effects of four aminoglycoside antibiotics: amikacin, gentamicin, kanamycin and tobramycin (author's transl)]. Drugeon HB, Courtieu AL. Ann Microbiol (Paris); 1979 Apr 01; 130A(3):331-43. PubMed ID: 114083 [Abstract] [Full Text] [Related]
17. In vitro susceptibility of recently isolated gram-negative bacteria to gentamicin, sisomicin, tobramycin, and amikacin. Knothe H. J Infect Dis; 1976 Nov 01; 134 SUPPL():S271-4. PubMed ID: 825585 [Abstract] [Full Text] [Related]
18. Suceptibility of aminoglycoside-resistant gram-negative bacilli to amikacin: delineation of individual resistance patterns. Acar JF, Witchitz JL, Goldstein F, Talbot JN, Le Goffic F. J Infect Dis; 1976 Nov 01; 134 SUPPL():S280-5. PubMed ID: 825587 [Abstract] [Full Text] [Related]
19. Evaluation of the resistance mechanisms of gentamicin-resistant Gram-negative bacilli and their susceptibility to tobramycin, netilmicin and amikacin. Maes P. J Antimicrob Chemother; 1985 Mar 01; 15(3):283-9. PubMed ID: 3997704 [Abstract] [Full Text] [Related]
20. [Antibacterial activity of amikacin towards gentamicin-resistant, Gram-negative bacilli]. Nicoletti G, Russo G, Toscano MA, Gismondo MR. Boll Ist Sieroter Milan; 1979 Jan 31; 57(6):713-7. PubMed ID: 121911 [Abstract] [Full Text] [Related] Page: [Next] [New Search]